Cardio

How to stent a sidebranch. Cappella knows how and has now supplemented CE mark for its Sideguard® system with Indian approval.

A new publication casts doubt on stenting of stable coronary artery disease patients as a supportable first treatment.

Diligent QC inspections have identified a potential problem with some of Cardiac Science’s AEDs, prompting a recall.

New Blood Pressure Profile app to be demonstrated on CSR’s Bluetooth low energy devices at Mobile World Congress to showcase market opportunity for growing mHealth space

Eight years after first European implantation Sorin’s Freedom Solo stentless pericardial aortic valve sees its first US patient.

It’s friday, what the heck, we’re allowed to “brainstorm”. Research work from Stanford’s Department of Engineering have presented a miniature, swimming robot which could theoretically end up drilling plaque out of occluded blood vessels.

UK’s Bradford Royal Infirmary has embarked on a much-publicised evaluation of Verathon’s Heartscape Vest in the hope that it will fulfill its promise of achieving early and efficient diagnosis of heart conditions including heart attack.

Boston’s drug-eluting stents have become the first to gain FDA clearance for use in heart attack patients.

Nice piece updating us on the Riata/Sprint Fidelis ICD lead situation.

We’re a truly schizophrenic lot aren’t we? We embrace technology like this, then moan that we have lax regulatory control. Regardless of the argument, the fact is that this tiny Japanese company’s PLLA stent is approved in EU, but not USA or Japan.

Initial results of ReCor’s REDUCE First-In-Man clinical study presented at “TRenD 2012” transcatheter renal denervation scientific meeting as company gains CE mark for its PARADISE™ system.

St Jude is pretty bullish about FFR measurement as a diagnostic tool in assessing coronary artery disease, based on favourable outcome from previous studies. It’s now supporting a country-specific evaluation of the cost effectiveness of an FFR-guided intervention strategy for patients with multivessel coronary artery disease in Japan, China, India, Korea, and Australia.

Solid figures, but it’s not quite all good news at Medtronic as sales in some divisions suffer, especially in USA.

Despite losing Hemostase revenue, Cryolife has reported record Q4 and significant annual revenue growth, giving it optimistic outlook for the near term as it enacts global strategic initiatives.

Freeze dried heart valve material holds promise as a scaffold. Researchers have investigated different techniques in order to optimise the resultant material.

Medtronic Inc’s Resolute Integrity™ Drug-Eluting Stent for treating coronary artery disease has been approved by the FDA, after studies showed consistent clinical performance among a wide range of patients, including individuals with diabetes.